R. Vela‐Navarrete

Comparison of a Phytotherapeutic Agent (Permixon) with an α-Blocker (Tamsulosin) in the Treatment of Benign Prostatic Hyperplasia: A 1-Year Randomized International Study

F.M.J. Debruyne, Gary G. Koch, Peter Boyle et al. · European Urology · 2002 · 172 citations

Urology, Medicine, Phytotherapeutic Agent +4

SERENOA REPENS TREATMENT MODIFIES BAX/BCL-2 INDEX EXPRESSION AND CASPASE-3 ACTIVITY IN PROSTATIC TISSUE FROM PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA

R. Vela‐Navarrete, Marta ESCRIBANO-BURGOS, Antonio López‐Farré et al. · The Journal of Urology · 2005 · 86 citations

Evaluation of the Clinical Benefit of Permixon and Tamsulosin in Severe BPH Patients—PERMAL Study Subset Analysis

F.M.J. Debruyne, Peter Boyle, Fernando Calais da Silva et al. · European Urology · 2004 · 73 citations

Thrombosis, Hypertension, Cardiovascular Disease +8

The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992–2002)

R. Vela‐Navarrete, Carmen González Enguita, J.V. García-Cardoso et al. · British Journal of Urology · 2005 · 69 citations

[Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study].

F. Debruyne, Gary G. Koch, P Boyle et al. · PubMed · 2002 · 58 citations